AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19022155 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 7851
Study 19022155 — intervention group
Group type: COMPARATOR
Intervention: Heparin + GPI
Number of subjects: 7851
Study 15849277 — intervention group
Group type: EXPERIMENTAL
Intervention: Open sea scuba air diving to 39 m (30 minutes bottom time)
Number of subjects: 8
Study 12610862 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin, etoposide, and cisplatin (BEP)
Number of subjects: 0
Study 12610862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, ifostamide, and either etoposide or vinblastine (VIP or VeIP)
Number of subjects: 0
Study 12610862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with autologous stem-cell rescue
Number of subjects: 0
Study 12610862 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of new active agents (paclitaxel, gemcitabine, irinotecan)
Number of subjects: 0
Study 10234295 — intervention group
Group type: EXPERIMENTAL
Intervention: OVEX + TAM
Number of subjects: 1579
Study 10234295 — intervention group
Group type: EXPERIMENTAL
Intervention: CHEM
Number of subjects: 1579
Study 10234295 — intervention group
Group type: EXPERIMENTAL
Intervention: CHEM + TAM
Number of subjects: 1579
Study 10234295 — intervention group
Group type: COMPARATOR
Intervention: TAM
Number of subjects: 1579
Study 8740091 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (T) of tamoxifen 30 mg
Number of subjects: 24
Study 8740091 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (R) of tamoxifen 30 mg
Number of subjects: 24
Study 8740091 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (T) of N-desmethyl-tamoxifen
Number of subjects: 24
Study 8740091 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (R) of N-desmethyl-tamoxifen
Number of subjects: 24
Study 30900512 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Self‐rehabilitation Contract (GSC) program
Number of subjects: 23
Study 28105576 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I + placebo
Number of subjects: 95
Study 28105576 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I + armodafinil
Number of subjects: 95
Study 28105576 — intervention group
Group type: COMPARATOR
Intervention: Armodafinil
Number of subjects: 95
Study 28105576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 26474811 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy followed by PCI
Number of subjects: 10064
Study 26474811 — intervention group
Group type: COMPARATOR
Intervention: PCI alone
Number of subjects: 10064
Study 25149383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligustrazine intervention (group A)
Number of subjects: 60
Study 25149383 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support (group B)
Number of subjects: 60
Study 25149383 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 60
Study 25149383 — intervention group
Group type: EXPERIMENTAL
Intervention: FGR group with treatment (animal experiment)
Number of subjects: 60
Study 25149383 — intervention group
Group type: COMPARATOR
Intervention: FGR group without treatment (animal experiment)
Number of subjects: 60
Study 22968413 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of four probiotics and four fibres
Number of subjects: 19
Study 22968413 — intervention group
Group type: COMPARATOR
Intervention: Placebo group receiving fibres only
Number of subjects: 19
Study 22968413 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 19
Study 17605839 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthful diet promotion intervention
Number of subjects: 1613
Study 17605839 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1613
Study 16194475 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg/nitrendipine 20 mg (E/N)
Number of subjects: 323
Study 16194475 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg (A)
Number of subjects: 323
Study 12970199 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-Pump Coronary Artery Bypass (OPCAB) surgery
Number of subjects: 7386
Study 12970199 — intervention group
Group type: COMPARATOR
Intervention: Conventional Coronary Artery Bypass Grafting (CABG) using Cardio-Pulmonary Bypass (CPB) technique
Number of subjects: 7386
Study 10853971 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg once daily
Number of subjects: 20
Study 10853971 — intervention group
Group type: COMPARATOR
Intervention: 200 mg twice daily
Number of subjects: 20
Study 8989057 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12
Study 8989057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1469293 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied 8% (w/v) verapamil hydrochloride in propylene glycol
Number of subjects: 0
Study 1469293 — intervention group
Group type: COMPARATOR
Intervention: Vehicle controls
Number of subjects: 0
Study 3975747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg t.i.d.)
Number of subjects: 20
Study 3975747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30955152 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiating joint attention condition
Number of subjects: 37
Study 30955152 — intervention group
Group type: COMPARATOR
Intervention: Responding joint attention condition
Number of subjects: 37
Study 30955152 — intervention group
Group type: EXPERIMENTAL
Intervention: Both joint attention conditions
Number of subjects: 37
Study 29316880 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly Structured (HS) format
Number of subjects: 370
Study 29316880 — intervention group
Group type: COMPARATOR
Intervention: IMRaD format
Number of subjects: 370
Study 25840784 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pain peripheralization
Number of subjects: 55
Study 24205802 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal blockade with 30 ml ropivacaine 7.5 mg/ml (n=36)
Number of subjects: 72
Study 24205802 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group, n=35)
Number of subjects: 72
Study 22494786 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E and C supplementation
Number of subjects: 120
Study 22494786 — intervention group
Group type: COMPARATOR
Intervention: Untreated OCU (OC users)
Number of subjects: 120
Study 22494786 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy females not using OCs)
Number of subjects: 120
Study 21416785 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable dosing of budesonide/formoterol (Symbicort, 80/4.5 microg and 160/4.5 microg)
Number of subjects: 0
Study 21416785 — intervention group
Group type: COMPARATOR
Intervention: Fixed dosing of budesonide/formoterol
Number of subjects: 0
Study 17452579 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (mean dosage 120 mg/day)
Number of subjects: 40
Study 17452579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15860863 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of antidepressant medications
Number of subjects: 472
Study 15860863 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of counseling services
Number of subjects: 472
Study 15860863 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe levels of depressive disorder
Number of subjects: 472
Study 15860863 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlates of depression
Number of subjects: 472
Study 15860863 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine screening, evaluation, and treatment
Number of subjects: 472
Study 12576955 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 69
Study 12576955 — intervention group
Group type: COMPARATOR
Intervention: Palpation technique
Number of subjects: 69
Study 10564319 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinaldehyde 0.1% gel combined with topical erythromycin 4% lotion
Number of subjects: 74
Study 10564319 — intervention group
Group type: COMPARATOR
Intervention: Topical erythromycin 4% lotion alone
Number of subjects: 74
Study 8768491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-site remote sensor
Number of subjects: 0
Study 8768491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile remote sensor
Number of subjects: 0
Study 8768491 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple displays monitored
Number of subjects: 0
Study 8768491 — intervention group
Group type: EXPERIMENTAL
Intervention: Event complexity (number of targets and redundancy of target images)
Number of subjects: 0
Study 1912447 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms dose of recombinant DNA hepatitis B vaccine (B-Hepavac II)
Number of subjects: 67
Study 1912447 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms dose of recombinant DNA hepatitis B vaccine (B-Hepavac II)
Number of subjects: 67
Study 7055183 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline
Number of subjects: 92
Study 7055183 — intervention group
Group type: COMPARATOR
Intervention: ethanol
Number of subjects: 92
Study 28887255 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper thermal blanket
Number of subjects: 50
Study 28887255 — intervention group
Group type: COMPARATOR
Intervention: Underbody thermal blanket
Number of subjects: 50
Study 27118107 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 8
Study 27118107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 24450931 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury Prevention Briefing (IPB) with facilitation package
Number of subjects: 33
Study 24450931 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury Prevention Briefing (IPB) with no facilitation package
Number of subjects: 33
Study 24450931 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 33
Study 22260366 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard intervention (12 postcards sent once a month for 12 months)
Number of subjects: 0
Study 22260366 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 20077278 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery training programme
Number of subjects: 21
Study 20077278 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 18727454 — intervention group
Group type: EXPERIMENTAL
Intervention: Eperisone 100 mg three times daily (t.i.d.)
Number of subjects: 160
Study 18727454 — intervention group
Group type: COMPARATOR
Intervention: Thiocolchicoside 8 mg twice daily (b.i.d.)
Number of subjects: 160
Study 15779223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous injection using 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 0
Study 15779223 — intervention group
Group type: COMPARATOR
Intervention: Infiltration injection using 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 0
Study 12753879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive counseling and outpatient telephone follow-up
Number of subjects: 223
Study 12753879 — intervention group
Group type: COMPARATOR
Intervention: Minimal counseling
Number of subjects: 223
Study 10607493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 10607493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger extract
Number of subjects: 0
Study 10607493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8646872 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 0.005% ointment, applied topically up to 100 gm/week, twice daily for up to four weeks
Number of subjects: 388
Study 8646872 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 388
Study 2025077 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐80
Number of subjects: 105
Study 2025077 — intervention group
Group type: EXPERIMENTAL
Intervention: UF‐205
Number of subjects: 105
Study 2025077 — intervention group
Group type: COMPARATOR
Intervention: Cell Saver (Cell Saver 4)
Number of subjects: 105
Study 6390802 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (Solu-Medrol) in addition to antibiotics and early surgical intervention
Number of subjects: 0
Study 6390802 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics and early surgical intervention
Number of subjects: 0
Study 31215197 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-week aerobic training group
Number of subjects: 30
Study 31215197 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 31038634 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention (follow-up at 7, 15, and 30 days after delivery)
Number of subjects: 85
Study 31038634 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telephone intervention)
Number of subjects: 85
Study 31038634 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 85
Study 28964538 — intervention group
Group type: EXPERIMENTAL
Intervention: UD sign
Number of subjects: 101
Study 28964538 — intervention group
Group type: COMPARATOR
Intervention: ABCD rule
Number of subjects: 101
Study 25113885 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine (2 mg/kg) and glucosamine (25 mg/kg) for 8 weeks
Number of subjects: 19
Study 25113885 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cyclosporine alone for 8 weeks
Number of subjects: 19
Study 23283367 — intervention group
Group type: EXPERIMENTAL
Intervention: MD‐DCs pulsed with autologous heat‐inactivated whole HIV
Number of subjects: 33
Study 23283367 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsed MD‐DCs
Number of subjects: 33
Study 21628339 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 207
Study 21628339 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 207
Study 21628339 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall grafts
Number of subjects: 207
Study 18434729 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10-40 mg)
Number of subjects: 1036
Study 18434729 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10-80 mg)
Number of subjects: 1036
Study 16413495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy administered in small groups
Number of subjects: 125
Study 12888783 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose ketamine
Number of subjects: 11
Study 12888783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 12888783 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose ketamine
Number of subjects: 11
Study 10704624 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals heterozygous for the 68‐bp insertion (844ins68 variant)
Number of subjects: 1025
Study 10704624 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals homozygous for the A(2756)G transition
Number of subjects: 1025
Study 10704624 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with polymorphic traits (C(677)T transition)
Number of subjects: 1025
Study 9078414 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy fiber‐supplemented formula (Isomil DF)
Number of subjects: 44
Study 9078414 — intervention group
Group type: COMPARATOR
Intervention: Soy formula (Isomil)
Number of subjects: 44
Study 8436706 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous pushing
Number of subjects: 32
Study 8436706 — intervention group
Group type: COMPARATOR
Intervention: Directed pushing
Number of subjects: 32
Study 3741730 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 250 mg
Number of subjects: 9
Study 3741730 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 500 mg
Number of subjects: 9
Study 3741730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 24913009 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 67
Study 25286914 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin 30 μg/kg per day for 24 hours
Number of subjects: 65
Study 25286914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 22550156 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete coronary revascularization (ICR) defined by diameter stenosis (DS) cutoffs ≥50%
Number of subjects: 2954
Study 20129826 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotubation using 50 ml of saline
Number of subjects: 213
Study 20129826 — intervention group
Group type: COMPARATOR
Intervention: No hydrotubation
Number of subjects: 213
Study 18842978 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminder for appointments (Intervention group)
Number of subjects: 173
Study 18842978 — intervention group
Group type: COMPARATOR
Intervention: No reminder (Control group)
Number of subjects: 173
Study 15869692 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent video game condition
Number of subjects: 48
Study 15869692 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent video game condition
Number of subjects: 48
Study 12648865 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (a combination of oral conjugated estrogen 0.625 mg and medroxyprogesterone acetate 5 mg daily)
Number of subjects: 135
Study 12648865 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT + MFP (HRT combined with oral monofluorophosphate 25 mg per day)
Number of subjects: 135
Study 12648865 — intervention group
Group type: COMPARATOR
Intervention: MFP (oral monofluorophosphate 25 mg per day)
Number of subjects: 135
Study 12648865 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 135
Study 12648865 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT + MFP
Number of subjects: 135
Study 12648865 — intervention group
Group type: COMPARATOR
Intervention: MFP
Number of subjects: 135
Study 10488413 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily
Number of subjects: 429
Study 10488413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 10488413 — intervention group
Group type: COMPARATOR
Intervention: Placebo/lamivudine
Number of subjects: 429
Study 8752839 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical phosphodiesterase inhibitor (CP80,633)
Number of subjects: 20
Study 8752839 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 20
Study 1872724 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of sublingual nifedipine
Number of subjects: 44
Study 1872724 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg of clonidine per os
Number of subjects: 44
Study 1872724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 6994586 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 8
Study 6994586 — intervention group
Group type: COMPARATOR
Intervention: d-amphetamine
Number of subjects: 8
Study 6994586 — intervention group
Group type: COMPARATOR
Intervention: Methysertide
Number of subjects: 8
Study 31095287 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 174
Study 31095287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 31095287 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (window cohort)
Number of subjects: 174
Study 28069320 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (32°C‐35°C) plus standard care
Number of subjects: 60
Study 28069320 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 26165587 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy
Number of subjects: 38
Study 26165587 — intervention group
Group type: COMPARATOR
Intervention: Retrograde intrarenal surgery
Number of subjects: 38
Study 24176495 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vaccination (day 5 after chemotherapy)
Number of subjects: 56
Study 24176495 — intervention group
Group type: COMPARATOR
Intervention: Late vaccination (day 16 after chemotherapy)
Number of subjects: 56
Study 17685701 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-aerobic exercises
Number of subjects: 12
Study 17685701 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation
Number of subjects: 12
Study 17685701 — intervention group
Group type: COMPARATOR
Intervention: Water-aerobic exercises
Number of subjects: 12
Study 17685701 — intervention group
Group type: COMPARATOR
Intervention: Passive rest
Number of subjects: 12
Study 15486392 — intervention group
Group type: EXPERIMENTAL
Intervention: TOF monitoring
Number of subjects: 30
Study 15486392 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment
Number of subjects: 30
Study 11295959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg/d)
Number of subjects: 409
Study 11295959 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil hydrochloride (240 mg/d)
Number of subjects: 409
Study 11295959 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 mg/d)
Number of subjects: 409
Study 11295959 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril maleate (10 mg/d)
Number of subjects: 409
Study 11295959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and verapamil
Number of subjects: 409
Study 9168293 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation
Number of subjects: 2609
Study 8287830 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thyroid therapy
Number of subjects: 35
Study 8287830 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/day for 28 days
Number of subjects: 35
Study 3552106 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 80 mg IV
Number of subjects: 36
Study 3552106 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 36
Study 30507887 — intervention group
Group type: EXPERIMENTAL
Intervention: Osseodensification drilling technique
Number of subjects: 12
Study 30507887 — intervention group
Group type: COMPARATOR
Intervention: Osteotome site preparation (Control)
Number of subjects: 12
Study 28675077 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of randomization procedures in school-based RCTs
Number of subjects: 0